Publications

Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle

Vishnu Kumarasamy, Jianxin Wang, Michelle Roti, Yin Wan, Adam P. Dommer, Hanna Rosenheck, Sivasankar Putta, Alec Trub, John Bisi, Jay Strum, Patrick Roberts, Seth M. Rubin, Costakis Frangou, Karen McLean, Agnieszka K. Witkiewicz & Erik S. Knudsen

See the Publication >

INX-315, an Oral, Potent and Selective CDK2 Inhibitor in Patients with CDK4/6 Inhibitor Resistant ER+/HER2-Breast Cancer or CCNE1 Amplified Solid Tumors

Antoinette R. Tan, MD, MHSc⁽¹⁾; Antonio Giordano, MD, PhD⁽²⁾; Catherine Shannon,
MD⁽³⁾; Carey Anders, MD⁽⁴⁾; Nashat Gabrail, MD⁽⁵⁾; Kevin Kalinsky, MD, MS⁽⁶⁾; Patrick
Roberts, PharmD, PhD⁽⁷⁾; Andrew Beelen, MD⁽⁷⁾; George Au-Yeung, MD, PhD⁽⁸⁾

⁽¹⁾Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, ⁽²⁾Dana-
Farber Cancer Institute, ⁽³⁾Mater Hospital, ⁽⁴⁾Duke Cancer Center, ⁽⁵⁾Gabrail Cancer Center
Research, (6)Emory Winship Cancer Institute, ⁽⁷⁾Incyclix Bio, LLC, ⁽⁸⁾Peter MacCallum Cancer Center

See the Publication >

INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors

Catherine Dietrich^1,2, Alec Trub³, Antonio Ahn^1,2, Michael Taylor^1,2, Krutika Ambani^1,2, Keefe T. Chan^1,2,
Kun-Hui Lu^1,2, Christabella A. Mahendra^1,2, Catherine Blyth^1,2, Rhiannon Coulson^1,2, Susanne Ramm^1,2,
April C. Watt^1,2, Sunil Kumar Matsa⁴, John Bisi³, Jay Strum³, Patrick Roberts³, and Shom Goel^1,2

Cancer Discov 2024;14:446–67

See the Publication >

INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1-amplified cancers

Alec G. Trub¹, John E. Bisi¹, Catherine Dietrich², Michael Taylor, Jay C. Strum¹, Shom Goel², Patrick J. Roberts^1
1Incyclix Bio, Durham, NC, United States, ²The Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

See the Publication >